r e v i e w T cells, some allergy-prone organs that are exposed to the environment 'program' , or imprint, preferential tissue-specific inflammatory effector T cell and memory T cell entry from the circulation to streamline immune surveillance, as many microbes are tissue tropic in virulence 12, 17, 22 .
T cells that are programmed to home to the small intestine are imprinted during the initial antigen priming to specifically express integrin α 4 β 7 and the chemokine receptor chemokine (C-C motif) receptor 9 (CCR9), expression of which enables restricted and regulated entry into the small intestine 23, 24 (Fig. 2) . In contrast, the signaturehoming receptors of skin-tropic T cells are the lectin cutaneous leukocyte antigen (CLA), which is derived from the glycosylation of PSGL1, in combination with the chemokine receptors CCR4 and CCR10 and, for some T cell subsets, CCR8 and CCR6 (Fig. 2) 20, [25] [26] [27] [28] [29] [30] [31] [32] . Low levels of the ligands for these receptors are constitutively expressed in the steady state to facilitate tissue-specific memory T cell homing and immune surveillance 30, [33] [34] [35] [36] . Higher levels of the ligands induced during inflammation promote increased tissuespecific effector T cell homing. Notably, mechanisms that facilitate gut-and skin-specific imprinting are dependent on tissue-specific dendritic cells and tissue-specific environmental cues 12, 22 . In the gut, CD103 + (α E β 7 integrin) lamina propria and Peyer's patch dendritic cells produce high concentrations of retinoic acid; retinoic acid enables these dendritic cells to imprint expression of the gut-tropic receptors α 4 β 7 and CCR9 on naive T cells [37] [38] [39] [40] [41] [42] . Likewise, skin dendritic cells can generate high concentrations of the active vitamin D3 metabolite, 1,25(OH) 2 D3, and then use it to induce CCR10 expression on T cells in higher mammals 22, 43 .
Studies suggest that the lungs and nasal-associated lymphoid tissue (NALT) also program T cells for tissue-specific homing 12, 44 . High endothelial venules in NALT express high amounts of peripheral node addressin (PNAd), the ligand for CD62L, the expression of which distinguishes NALT from other mucosal-associated tissues, such as Peyer's patches. Programmed allergen-specific T cell entry into NALT through interactions with PNAd promotes allergic rhinitis 44 . Though not definitive, lung-specific imprinting is suggested by human studies in which CD8 + T cells specific for respiratory, but not systemic, viruses were selectively enriched in human lungs, analogous to the enrichment of CLA hi T cells specific for skin-tropic but not systemic viruses in the skin 45, 46 . Steady-state human lung-resident T cells are also reported to be enriched for CCR5, CCR6, chemokine (C-X-C motif) receptor 3 (CXCR3) and the integrins VLA1 (α 1 β 1 ), α E (α E β 7 or CD103) and VLA4 (α 4 β 1 ) [47] [48] [49] . However, the cellular mechanisms and environmental cues that promote lung-specific T cell imprinting have not been elucidated.
A consequence of naive T cell priming at any tissue site is the generation of memory T cells after the resolution of inflammation; recently a category of memory T cells known as tissue-resident memory T cells (T RM ) has been characterized 50 (Fig. 1) . Based on functional traits that are linked to the ability to traffic to either secondary lymphoid tissue or peripheral tissue, memory T cells are classified into 'central memory' and 'peripheral memory' T cells 51 (Fig. 1) . Central memory T cells preferentially traffic between secondary lymphoid tissue and the systemic circulation, whereas effector memory T cells preferentially home to peripheral tissue from the blood 14, 15, 51 (Fig. 1) . A fraction of antigenprimed effector T cells differentiate into long-lived antigen-specific npg r e v i e w (MADCAM1), oral tolerance is abrogated, as T reg cells fail to traffic from the MLN to the lamina propria 67 . In contrast, in the presence of pro-inflammatory cytokines, such as IL-15, retinoic acid can act as an adjuvant to promote inflammatory responses to dietary antigen 68 . In the skin, skin-tropic effector memory T cells and skintropic T reg cells share receptor profiles comprised of CCR4, CLA and CCR8, which suggests that common environmental cues may imprint proinflammatory and anti-inflammatory T cell homing pathways to the skin 13, 69 . T reg cells exert their suppressive effects by localizing to lymphoid organs during the induction of the immune response and to peripheral tissues during the ongoing immune response 13, 67, [70] [71] [72] . For example, oral tolerance to ingested soluble antigen is initiated during the inductive phase of the immune response in the MLN, and oral tolerance is abrogated after mesenteric lymphadenectomy and in CCR7-deficient mice 71 . An altered epithelial barrier may allow proinflammatory cytokines or persistent allergen exposure to tip a programmed tissue-tropic pathway that promotes tolerance to innocuous allergens toward one that induces allergic inflammation. memory T cells, some of which persist throughout the lifetime of the host 50 . Recent studies have suggested that large pools of tissue T RM cells with enhanced effector capabilities persist in uninflamed peripheral organs, such as the lung, skin and gut, and provide a first line of defense against pathogens ( Fig. 1 ) 32, 48, 50, [52] [53] [54] [55] [56] [57] [58] .
Tissue-resident memory T cells and allergic disease
In the context of allergic diseases, programmed homing pathways increase the likelihood that tissue-patrolling memory T cells will encounter activated dendritic cells that present a cognate allergen in the tissue as well as in the draining lymph nodes. Sensitization to environmental allergens at the epithelial surfaces will generate long-lived allergen-specific memory T cells that are programmed to home to the mucosal and epithelial surfaces for immune surveillance. Concordantly, allergen-induced pathological activation of the epithelial barrier, through the production of cytokines such as IL-33, TSLP and IL-25, enhances the activation and maturation of T H 2-priming dendritic cells. Prior and recurrent allergen exposure will also generate higher frequencies of recirculating allergen-specific memory T cells, as well as long-lived allergen-specific T RM cells at the tissue sites of allergen exposure (Fig. 1) . Thus, instead of being a very rare event, programmed homing pathways increase the likelihood that after allergen re-exposure, tissue-patrolling recirculating memory T cells and T RM cells encounter cognate allergen presented by dendritic cells, particularly if the epithelial barrier is compromised 59 .
Programmed regulatory T cell trafficking to the epithelial barrier Programmed trafficking pathways that promote T cell-mediated allergic inflammation are also used by regulatory T (T reg ) cells to rein in inappropriate responses at mucosal and epithelial surfaces. The dendritic-cell-derived factors retinoic acid and 1,25(OH) 2 D3 can be either proinflammatory or anti-inflammatory [60] [61] [62] [63] [64] [65] . In the intestine, retinoic acid derived from CD103 + mucosal dendritic cells induces forkhead box P3 (Foxp3) + T reg cell differentiation from naive T cells after in vivo activation 63, 65, 66 . Retinoic acid also imprints Foxp3 + adaptive T reg cells in the mesenteric lymph node (MLN) to acquire expression of α 4 β 7 and CCR9 to enable homing to the small intestine from the MLN 61 . In mice deficient for integrin β 7 or the integrin ligand mucosal vascular addressin cell adhesion molecule 1 npg r e v i e w memory CD8 T cells from the circulation into the lung, skin and gut is more restricted compared to other peripheral organs 55, 56 . In infectious models, memory CD8 T cell persistence is antigen dependent in the lung and is antigen independent in the skin and intestine 55, 73 . Re-exposure to antigen can also increase the size of the T RM cell pool 57 . T RM CD4 and CD8 T cells can be activated by antigen-presenting dendritic cells in tissue before activation by dendritic cells in the draining lymph nodes 54, 58, 74 . In addition to a functional role for T RM cells in host immunity to pathogens, a functional role for T RM cells has been shown in chronic inflammatory disease 53, 75 . Memory CD4 T cells derived from human psoriasis skin and grafted into mouse dermis are sufficient for induction of disease in a xenotransplanation model of psoriasis 75 .
In humans, large reservoirs of T RM cells have been reported in the skin and lungs 32, 48 . Twice as many T RM cells are present in healthy skin compared to blood, and 98% of all CLA + T cells are found in the skin in the steady state 32 . Likewise, steady-state T RM cells in the human lung are equivalent in number to the circulating steady-state memory T cells in the blood 48 . Consistent with in vivo mouse studies, these lung T RM cells are not anergic, and they produce effector cytokines after activation 48 . Moreover, only lung T RM cells robustly proliferated ex vivo in response to influenza virus, a respiratory pathogen, in an antigen-specific manner, whereas skin-resident and blood T cells did not 48 .
It is unclear whether and how T RM cells modulate allergic inflammation. The traditional thinking has been that the hugely expanded pool of allergen-specific effector T cells derived from dendritic-cellactivated central memory T cells express inflammatory chemokine receptors that enable their exit from lymphoid organs and their entry into peripheral sites of inflammation from the circulation 76 . Although the majority of effector T cells in a recall response are probably derived from central memory T cells, this paradigm may require revision with the appreciation that pre-existing tissue pools of T RM cells can be activated by tissue-resident dendritic cells. T RM cells may locally modulate allergic responses during the initiation phase of an allergenspecific recall response within the first few days after exposure, before lymph-node-derived amplified allergen-specific effector T cell entry into inflamed tissue from the bloodstream.
Inflammatory T H 2 cell trafficking CD4 T H cells have a pivotal role in mediating adaptive immunity to diverse pathogens and in promoting autoimmune diseases and allergic inflammation 77 . During inflammation and after T cell receptor (TCR) activation, specific cytokines derived from the innate immune system and distinct master transcription factors program naive T H cells to differentiate into T H 1, T H 2, T H 17, T reg and follicular T helper (T FH ) cell subsets 77 . The master transcriptional regulators T-box 21 (T-bet), GATA binding protein 3 (GATA3), RAR-related orphan receptor γ (ROR-γT), FOXP3 and B cell CLL/lymphoma 6 (BCL6) drive T H cell subset differentiation and impart specificity of T H cell lineage function through the production of signature effector cytokines 77 (Fig. 3) . Repeated antigen exposure and progressive lineage polarization also promote terminal T H 1 and T H 2 cell differentiation through epigenetic modifications at the Ifng and Il4 loci to enable rapid effector cytokine production after antigen rechallenge 78 . Polarizing cytokines and master transcription factors that promote T H 1, T H 2 and T H 17 cell lineage differentiation also program the expression of unique combinations of inflammation-specific chemokine receptors on T H cell lineages during priming 13, 15, 79 (Fig. 3) . Thus, T H 2 cells are programmed during lineage differentiation to selectively express the chemokine receptors CCR4, CCR8 and, in humans, the prostaglandin D2 chemoattractant receptor DP2 or CRTH2 (refs. [79] [80] [81] , which are associated with T H 2-type inflammation.
T H 2 cell heterogeneity T H 2 cells can also be divided into an IL-4 hi IL-5 lo subset and a more differentiated IL-4 lo IL-5 hi subset, which can be distinguished by their expression of CCR4 or CCR8, respectively 29, 82 . Upregulation of CCR4 expression on T H 2 cells occurs rapidly after TCR ligation irrespective Although it was previously believed that highly differentiated T helper subsets are fixed with regard to lineage differentiation, plasticity in T H 17, T reg , T FH and T H 2 cell lineage differentiation is now appreciated, as is the fact that additional T H 2 cell subsets exist in vivo during chronic inflammation [88] [89] [90] . Virus infection and the induction of interferons reprogram antigen-specific, IL-4-producing GATA3 + T H 2 memory cells to become T H 2+1 cells that coexpress GATA3 and T-bet and secrete both IL-4 and interferon γ (IFN-γ) 88 . Likewise, T H 2 memory cells differentiate into a subset of IL-17-producing T H 2 cells that coexpress GATA3 and ROR-γT in severe chronic allergic inflammation that manifests a robust mixed neutrophilic and eosinophilic infiltrate in vivo 89 .
This heterogeneity of T H 2 cells should be kept in mind, as the original studies that elucidated T H cell subset biology were primarily conducted in tissue culture in the presence of neutralizing antibodies to generate pure T H cell lineages. During chronic inflammation in the absence of neutralizing antibodies in vivo and in the setting of genetic and environmental heterogeneity, human allergic disease is more complex and involves the simultaneous production of multiple cytokines. This is concordant with the current appreciation that human asthma is a heterogeneous disease and that therapeutic strategies that target a single T H 2 cell cytokine may only be effective in subpopulations of patients with asthma in which the therapeutic intervention is matched to the underlying pathophysiology 91, 92 . Thus, ex vivo studies of human peripheral blood T cells have not provided a clear cut correlate of T H 1 and T H 2 effector cell cytokine production and the signature chemokine receptors that are associated with pure T H 1 and T H 2 lineage-differentiated cells 16, 93 . It therefore follows that T cell-mediated allergic disease probably involves multiple chemokines and their receptors, the relative roles of which will vary depending on the affected organ and the temporal phase of the disease. We illustrate these points in the following sections.
T lymphocyte trafficking in atopic disease Atopic dermatitis. The role of CD4 + T cell effector functions in the pathogenesis of atopic dermatitis has been established in both mouse and human studies 94, 95 . In human atopic dermatitis, a number of skinhoming trafficking receptors, such as CLA, CCR4, CCR10 and CCR8, as well as their ligands, have been implicated and reported to correlate with disease activity 94, [96] [97] [98] [99] . Although the contributions of CCL17 and CCL27 in the recruitment of human memory CD4 T cells from the blood to the sites of skin inflammation are well established, a correlation of skin CCL17 and CCL27 transcripts with specific inflammatory human disease phenotypes has not been found 100 . In contrast, comparative analyses of all known chemokine RNA transcripts in healthy skin from control individuals and lesional skin from individuals with different chronic inflammatory skin disorders found significant and specific induction of the chemokines CCL1 and CCL18 in inflamed atopic dermatitis skin 34, 101 . Currently, the receptor for CCL18 is not known, although CCL18 binds skin-tropic CLA + memory T cells in patients with atopic dermatitis and induces in vivo migration of human memory T cells 102 . Additionally, microarray analyses have revealed that expression of the enzyme fucosyltransferase VII (FucT-VII), which regulates CLA expression, as well as the chemokine receptors CCR4 and CCR10, was significantly elevated in blood CD4 + T cells from individuals with atopic dermatitis compared to healthy controls 103, 104 . Notably, the frequency of CLA + blood T cells correlates with disease activity and skin inflammation in both contact hypersensitivity and atopic dermatitis 105 . Additional studies have suggested a role for chemokine (C-X3-C) receptor 1 (CX3CR1) and its ligand, CX3CL1, in active atopic dermatitis and are concordant with studies that suggest a role for CX3CR1 in asthma [106] [107] [108] .
The in vivo role of trafficking receptors that regulate T cellmediated atopic skin inflammation has recently been clarified in two complementary studies that used a 7-week treatment schedule in a mouse model of chronic atopic dermatitis 109 . CCL27 promotes atopic dermatitis in this model 28 . Recent studies highlighted how the kinetics of chemokine and chemokine-receptor expression, tissuespecific T cell trafficking and tissue reservoirs of antigen-specific T cells might regulate cutaneous inflammation during acute, recurrent or chronic allergen exposure (Fig. 4) 29, 110 . CCR4 is essential for the acute entry of T cells into the skin through the cutaneous vasculature and drives atopic inflammation in antigen-naive skin, in which pre-existing skin-resident reservoirs of antigen-specific memory T cells are absent 110 . Thus CCR4 is crucial for T cell entry into the skin during the initiation phase of cutaneous allergic inflammation, which is concordant with the rapid kinetics of the induction of its ligand, CCL17, in skin endothelium and with findings in other models of acute cutaneous inflammation 25, 111 . However, after repeated cutaneous allergen sensitization, CCR4 is not necessary for the entry of T H 2 cells from cutaneous vascular beds into the skin to sustain chronic eosinophilic atopic inflammation 29 . In this setting, pre-existing skin pools of allergen-specific memory T H 2 cells are probably sufficient to initiate and drive local inflammatory responses through effector cytokine production after activation by skin-resident antigenpresenting cells. In contrast, in this setting, both CCR8 and its newly described second ligand, mCCL8 (a ligand for CCR8 in the mouse), are essential for promoting IL-5-driven eosinophilic inflammation in chronic atopic dermatitis 29 . After 7 weeks of treatment, when peak atopic inflammation is manifest, mCCL8 is the only T cell-attracting chemokine that is significantly induced in sensitized skin, and its expression is several folds higher than those of CCL1, CCL17 and CCL22. Moreover, trafficking of CCR8 + T H 2 cells, which are enriched for IL-5 and the IL-25 receptor, into allergen sensitized skin is essential for driving skin inflammation, as both IL-5 and IL-25 are cytokines that amplify eosinophilic inflammation (Fig. 4) 5, 112 .
Asthma. The mechanisms of T cell-mediated inflammation have been extensively characterized in human asthma and in mouse models of allergic pulmonary inflammation and have identified CD4 + T H 2 cells as being central to the pathogenesis of human asthma. This concept has been established through studies of the specific effects of T H 2 cytokines and the in vivo findings that T H 2 cells are sufficient to initiate and drive asthma pathogenesis 59, 77, 113, 114 . However, it is now well appreciated that other T cell subtypes, such as T H 1, T H 17, T reg , natural killer T (NKT) and innate helper type 2 cells coexist with T H 2 cells and contribute to the pathogenesis of asthma 113, 114 . Furthermore, the plasticity of T H 2 lineage differentiation, such that T H 2 cells may undergo additional differentiation to coproduce IFN-γ or IL-17, has been shown in mouse models of allergic pulmonary inflammation and, for IL-17, in human asthma 88, 89 . Given the chronicity of human asthma, the possibility that various environmental npg r e v i e w (BLT1), which is expressed by T H 1, T H 2 and T H 17 cells and induces their migration (unpublished observations and ref. 124) . A deficiency of BLT1 leads to a defect in early T cell accumulation in the airways in a model of allergic pulmonary inflammation that involves active allergen immunization and the generation of allergen-specific IgE 124, 125 . Mast cells also produce the chemokines CCL1, CCL17 and CCL22 (refs. 34,126,127) . Mast cell release of CCL1 may be key for early T H 2 cell recruitment through the CCR8 receptor, as was shown in a mastcell-dependent model of chronic allergic inflammation 126 . The prostaglandins released include prostaglandin D2 (PGD2), the receptors for which are the GPCRs DP1 and DP2. DP2 is also called CRTH2 (chemoattractant receptor-homologous molecule expressed on T H 2 cells) and is expressed by human T H 2 cells. PGD2 induces migration and activation of T H 2 cells through CRTH2, and polymorphisms of CRTH2 are associated with an increased risk for asthma in Chinese children and African Americans but a reduced risk for asthma in German children 81, 128, 129 . The rapid kinetics of mast cell-mediator release suggests that the recruitment of T cells in this early phase probably involves lung-resident allergen-specific memory cells.
During the late, T cell-mediated effector phase of asthma, initial T cell recruitment is probably facilitated by allergen-and damageassociated molecular pattern-mediated activation of pattern recognition receptors, such as Toll-like receptors (TLRs) or C-type lectins on innate immune cells, or by direct activation of epithelial cells by allergens. This induces the production of T H 2-promoting cytokines and chemokines by epithelial cells and innate tissue leukocytes and an initial phase of STAT6-independent recruitment of a small number of allergenspecific T cells into the lungs 121 . The kinetics of T cell recruitment in this initial phase suggests that it may also involve lung-resident allergenspecific memory and effector cells. For example, TLR activation and Debbie Maizels Figure 4 Trafficking of T H 2 cell subsets into the skin during the acute and chronic phases of atopic dermatitis. During the acute phase of atopic dermatitis, the initiation of inflammation is dependent on T H 2 cell entry into inflamed skin by CCR4 and the CCR4 ligand CCL17, which is upregulated in inflamed postcapillary venules. During the chronic phase of atopic dermatitis, the pool of allergen-specific skin tissue T RM cells is increased as compared to in the acute phase, and these allergen-specific T RM cells can initiate inflammation independent of CCR4-dependent T H 2 cell entry from the blood. Repeated prior allergen exposure also leads to the in vivo generation of the more differentiated CCR8 + IL-5 hi T H 2 cell subset in the chronic phase. Allergen challenge induces production of the CCR8 ligand, mCCL8, in the skin. mCCL8-dependent trafficking of IL-5 hi CCR8 + T H 2 cells into the skin drives eosinophilic skin inflammation in the chronic phase of atopic dermatitis in the mouse model.
exposures that induce recurrences and exacerbations throughout the course of disease cumulatively modulate the phenotype of an individual's allergic inflammation is not surprising. For example, respiratory viral infections and environmental mold exposure have been shown to be key variables in the exacerbation of allergic asthma [115] [116] [117] [118] .
The clinical presentation of asthma led us to focus our efforts on dissecting the mechanisms that underlie T cell trafficking and inflammation in the lung in the context of the asthmatic response, which can be divided into an early and a late phase 119 . The early phase of the asthmatic response occurs rapidly (within 5-60 min of allergen exposure) as a result of mast cell degranulation and mediator release and is characterized by airway swelling and bronchoconstriction, which results in a corollary decrease in airway airflow (Fig. 5) 119 . The early phase response often resolves but is followed several hours (>4) later by a more severe late phase response, which is induced by the infiltration of inflammatory cells, such as T cells and eosinophils in the airways, and is also associated with reduced airway airflow 119 . The late phase asthmatic response can last for extended periods of time 120 . Moreover, recurrent and constant exposure to inciting allergens drives inflammation and permanent airway remodeling in individuals with chronic asthma 119 . We first showed that T cell trafficking is necessary for asthmatic inflammation by establishing the essential requirement of GPCR signaling in allergic airway inflammation, for which we used an adoptive transfer model of asthma 121, 122 . T cell trafficking during the early and late phase asthmatic response involves multiple trafficking receptors, which are regulated by both innate and adaptive pathways and are summarized below and reviewed in more detail in ref. 123 (Fig. 5) .
Airway mast cells are the innate cells that are crucial for the early phase recruitment of T cells and initiation of the asthmatic response. When sensitized individuals inhale an allergen, pre-existing allergenspecific immunoglobulin E (IgE) leads to the crosslinking of mast cell IgE Fc receptors and the release of T H 2-type effector cytokines, inflammatory mediators, leukotrienes, prostaglandins and inflammatory chemokines by mast cells into the airways (Fig. 5) . Among the leukotrienes released by mast cells, leukotriene B 4 (LTB 4 ) is rapidly generated within minutes of exposure from membrane lipids and is the lipid chemoattractant ligand for the GPCR leukotriene B 4 receptor 1 npg r e v i e w its ligands in the bronchoalveolar lavage fluid, although CCR4 was required for efficient tissue entry of T H 2 cells in an adoptive transfer model of acute allergic pulmonary inflammation 49, 146 . In a recent study, CCR4 + T cells in the peripheral blood positively correlated with asthma severity in a cohort that included subjects with mild asthma as well as steroid-dependent subjects with moderate to severe asthma, and ex vivo production of CCL17 was higher in bronchial biopsy explants from subjects with asthma compared to healthy controls 147 . Additionally, studies of airway allergen challenge and genome-wide association have implicated CX3CR1 and its ligand CX3CL1 in human asthma 108, 148 . A recent study provided a possible mechanism for this association by showing that CX3CR1 signaling aided T H 2 cell survival and maintenance to drive allergic pulmonary inflammation 107 . Facilitating the long-term persistence of allergen-specific memory and effector T cells is also a mechanism by which the CCR8 pathway may promote chronic allergic inflammation 149 .
To define the transcriptional signals that regulate the induction of inflammatory chemokines and amplify T cell recruitment into the asthmatic lung, we used an adoptive transfer model of acute allergic inflammation and showed that it is STAT6 dependent 121 . T cell recruitment was dependent on STAT6 expression by a resident lung cell, which we subsequently showed to be from a subset of CD11b + CD11c + myeloid pulmonary dendritic cells, concordant with findings from other groups [150] [151] [152] . Thus, in this model of acute asthma, Stat6 −/− mice had Figure 5 Chemokine-regulated T H cell trafficking into the lung during the early and late phases of the asthmatic response. During the early phase allergic airway response (left), allergen-IgE complexes stimulate airway mast cells to degranulate and release acute mediators such as histamine, tumor necrosis factor α (TNF-α), LTB 4 , PGD2 and the chemokine CCL1. LTB 4 , PGD2 and CCL1 recruit T H 2 cells into the airways through BLT1, CRTH2 and CCR8, respectively. T lymphocyte trafficking during the late phase allergic airway response (right) is facilitated by innate cells, such as macrophages and myeloid dendritic cells (mDCs). Allergeninduced TLR activation induces macrophage and epithelial cell release of chemokines such as CXCL10 and CCL20. These chemokines recruit an initial wave of T cells into the airways through their receptors, CXCR3 and CCR6. IL-4 and IL-13 produced by activated lung allergen-specific T RM cells stimulate mDCs to release the chemokines CCL17 and CCL22 in a STAT6-dependent fashion. These chemokines amplify the subsequent recruitment of T H 2 effector cells, which are generated in lung draining lymph nodes, into the airways from the circulation by the T H 2 cell receptor CCR4. IL-4 and IL-13 also induce the differentiation of alternatively activated macrophages, which produce CCL17 to promote CCR4-dependent T H 2 cell recruitment. CCR8 and CX3CR1 are also probably involved in T cell recruitment into the lung during the late phase allergic airway response. CCR8 and CX3CR1 are implicated in human asthma and in mouse models of airway inflammation. The CCR8 ligand mCCL8 is upregulated in mouse models of allergic airway inflammation, but the cellular sources of mCCL8 in the lung have not been defined. The CX3CR1 ligand, CX3CL1, is induced in airway smooth muscle cells, lung endothelium and epithelial cells after allergen challenge.
allergen exposure are reported to induce CXCL10 and CCL20 production by macrophages and epithelial cells 123, 130 . The cognate receptors of CXCL10 and CCL20, CXCR3 and CCR6, respectively, are expressed by human T cells that infiltrate the lungs during allergic inflammation, particularly the airways 24 h after allergen challenge 49, 131, 132 . Moreover Ccr6 −/− mice have diminished airway hyper-responsiveness and allergic inflammation, and adoptive transfer of Ccr6 +/+ T cells into Ccr6 −/− mice increases allergic lung inflammation 133, 134 . Additionally, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) enhances the production of CCL20 by epithelial cells, perpetuating allergic inflammation through increased recruitment of CCR6 + memory and effector T H 2 cells into the airways 135 . Likewise, findings with Cxcl10 −/− and CXCL10 transgenic mice suggest that CXCR3 + T cell recruitment enhances allergic pulmonary inflammation 136 .
After the initial trafficking of T cells into the airways, T H 2 cell recruitment into the lungs is markedly amplified after T cell activation by mature dendritic cells in the draining lymph node, where T cells also undergo rapid proliferation 76 . The chemokine receptors CCR4, CCR8 and, possibly, CX3CR1 are the likely key chemokine receptors that regulate T H 2 cell recruitment into the lung during this phase. Concentrations of CCR4, CCR8 and their ligands are elevated in the lung or the bronchoalveolar lavage fluid of patients with asthma and in mouse models after allergen challenge [137] [138] [139] [140] . However, deletion of CCR4 and CCR8 receptors in mouse models of asthma and in human studies has yielded conflicting results 126, [141] [142] [143] [144] [145] [146] . Thus, aside from in two studies 126, 141 , CCR8 has not been shown to drive T H 2-type effector cell recruitment in models of allergic airway inflammation 126, 141, 143, 145, 146 . Likewise, 24 h after allergen challenge of steroid-naive subjects with mild asthma, there was no difference in the expression of CCR4 or npg r e v i e w significantly lower production of the T H 2 cell-attracting chemokines CCL17 and CCL22, as well as decreased induction of the eosinophilattracting chemokines CCL11 and CCL24. Moreover, CCL17, CCL22 and CCL11 were produced in a STAT6-dependent fashion in a 4-week active immunization model of allergic pulmonary inflammation 153 . In contrast, the transcriptional signals that regulate the induction of CCR8 and CX3CR1 in the allergic lung are not as well defined. Lung mCCL8 induction was STAT6 independent in a chronic 4-week active immunization model 153 . With respect to other T helper subsets, it is notable that T reg cells express the chemokine receptors CCR4 and CCR8 and, thus, may be recruited by the release of CCL1 during the early phase asthmatic response and the release of CCL17, CCL22 and mCCL8 during the late phase asthmatic response 69 .
Food allergy. In humans, allergen-specific T H 2 cells are essential for triggering non-IgE-mediated food allergies as well as maintaining type I IgE-mediated allergic responses. In allergic individuals, allergen-specific T cells in the blood proliferate more in response to food allergens compared to in non-allergic individuals, and human milk-specific T cells derived from the duodenum have a dominant T H 2-type cytokine secretion profile 154, 155 . After food challenges, the duodena of symptomatic individuals contain increased numbers of IL-4 + CD4 + T cells associated with IgE + cells that were mostly mast cells despite lacking food-allergen-specific serum IgE 156 . With regard to programmed organ-specific trafficking molecules, the integrin α 4 β 7 is selectively increased in lymphocytes stimulated with β-lactoglobulin in children allergic to cow's milk 157 . Peach-protein-allergen-specific T cell clones are also selectively enriched for α 4 β 7 and lack expression of CLA 158 . Thus food-allergen-specific T cells in humans are imprinted with gut-specific homing receptors. Milk-induced skin urticaria is also a common manifestation of milk allergy in young children, and milk exposure induces symptoms of eczema in individuals with atopic dermatitis 159, 160 . Notably, milk-induced urticaria and atopic eczema are both associated with increased circulating concentrations of allergenspecific T lymphocytes, which express CLA 159, 160 . Additionally, a recent human study found that anaphylactic peanut allergy is associated with an increased frequency in the number of blood IL-5 − IL-4 + peanut-specific T H 2 cells and IgE responses 161 . Conversely, blood IL-5 + IL-4 + peanut-specific T H 2 cells are associated with IgE-independent allergic eosinophilic gastroenteritis 161 . Extending these observations, the majority of peanut-allergen-specific blood CD4 T cells express CCR4 in individuals with a history of peanut anaphylaxis and peanutspecific IgE, and peanut-allergen-specific cell lines from these individuals primarily produce IL-4 (ref. 162) .
In the mouse, CCR7 expression on T reg cells is crucial for the induction of oral tolerance in the MLN, and T reg cells are directed to home to the gut lamina propria by MADCAM1 (refs. 67,71) . In a mast-cell-dependent mouse model of chronic food allergy in which inflammation is induced in the small intestine and manifests as allergic diarrhea, allergenspecific T cells are induced in the MLN and traffic to the small intestine 163 . In this model, increased numbers of T H 2 cytokines and the CCR8 and CCR4 ligands CCL1, CCL17 and CCL22 are upregulated in the inflamed small intestine 163 . In this same model, CCR6 is crucial for T cell trafficking to the small intestine and for driving npg r e v i e w IgE-independent T H 2 cell inflammation and allergic diarrhea 164 . Thus, chemokine receptors associated with allergic airway inflammation also seem to drive allergic inflammation in the gut.
Therapeutic targeting of leukocyte trafficking in allergy
We suggest that programmed tissue-specific T cell trafficking pathways during immune surveillance and inflammation contribute to the propensity of the skin, gut and lung for developing allergic diseases. Blocking tissue-and inflammation-specific trafficking pathways provides an opportunity for developing new targeted therapies for inflammation and allergic diseases and is actively being pursued ( Table 1) . Integrins were the first category of trafficking receptors to be targeted for therapy. Efalizumab, an antibody to CD11a that inhibits skin-homing CLA + T cell entry into the skin, was the first migration-inhibitory drug to be approved by the US Food and Drug Administration, and although it was initially approved for the treatment of psoriasis, it was also reported to be effective in some individuals with atopic dermatitis 165 . Among the chemoattractant receptors, the first drug to successfully reach phase 3 clinical trials for an inflammatory disease was, in fact, an antagonist for another tissue-specific homing molecule, CCR9, for the treatment of Crohn's disease. With regard to allergic inflammation, based on population-based genetic studies of an association of CRTH2 polymorphisms with allergic disease, many companies are actively pursuing inhibitors of CRTH2, some of which have recently completed phase 2 trials 81, 128, 129, 166 .
Other chemokine receptors being targeted for anti-allergic therapy are CCR3 and CCR4. An advantage of anti-migration-based therapy is that the likelihood of toxicity is less than that of immunosuppressive therapy. However, a caveat of extended anti-integrin-based therapies has been an unpredicted increased risk for developing fatal progressive multifocal leukoencephalopathy 167 .
In developing therapies based on anti-chemokine receptors, as we highlight in this review, the kinetics of inflammation-driven chemokine induction and T cell chemokine receptor expression during chronic allergic disease dictates the relative roles of different ligand-receptor pairs during distinct phases of disease and in different compartments. Large pre-existing pools of tissue-resident allergen-specific memory T cell pools also probably influence migration-inhibitor-based therapies. Though classical T H 2 cells are the main orchestrators of allergic inflammation through the production of T H 2 effector cytokines, other T helper subsets contribute to allergic inflammation. These factors reflect the importance of multiple T cell trafficking receptor pathways in allergic inflammation. Thus, the strategic design of new therapeutic agents directed against trafficking-receptor pathways for the treatment of allergic inflammation requires an appreciation of these multiple factors.
